StockData
Pfizer Inc logo

Pfizer Inc (PFE) stock

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3048% above fair value
$28.06−0.41 (-1.44%)

Close on Nov 18, 2026Market cap $159.93BP/E 36.9Yield 6.13%

Earnings

Pfizer's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 2, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$16.60B
-0.6% on a year earlier
Adjusted (3) Diluted EPS, Q3 FY2026
$0.87
$0.87 a year earlier
Latest guidance
Lowered
Nov 3, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of Pfizer's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 2, 2027Expected–––––
Q3 FY2026ended Sep 27, 2026Nov 3, 2026before the open$16.60B-0.6%$0.56$0.87Release
Q2 FY2026ended Jun 28, 2026Aug 4, 2026before the open$15.03B+2.3%-$0.04$0.77Release
Q1 FY2026ended Mar 29, 2026May 5, 2026before the open$14.50B+5.8%$0.47$0.75Release
Q4 FY2025ended Dec 31, 2025Feb 3, 2026before the open$17.60B-1.1%-$0.29$0.66Release
Q3 FY2025ended Sep 28, 2025Nov 4, 2025before the open$16.70B-5.6%$0.62$0.87Release
Q2 FY2025ended Jun 29, 2025Aug 5, 2025before the open$14.70B+10.5%$0.51$0.78Release
Q1 FY2025ended Mar 30, 2025Apr 29, 2025before the open$13.70B-8.1%$0.52$0.92Release
Q4 FY2024ended Dec 31, 2024Feb 4, 2025before the open$17.80B+25.4%$0.07$0.63Release
Q3 FY2024ended Sep 29, 2024Oct 29, 2024before the open$17.70B+34.1%$0.78$1.06Release
Q2 FY2024ended Jun 30, 2024Jul 30, 2024before the open$13.30B+4.7%$0.01$0.60Release
Q1 FY2024ended Mar 31, 2024May 1, 2024before the open$14.90B-18.6%$0.55$0.82Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Pfizer's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenueFY2026$60.50B – $62.50B$59.50B – $62.50BRaisedAug 4, 2026
RevenuesGAAPFY2026$62.00B – $64.00B–NewNov 3, 2026
Adjusted (3) diluted EPSnon-GAAPFY2026$2.95 – $3.05–NewNov 3, 2026
Adjusted (3) diluted EPSnon-GAAPFY2026$2.80 – $3.00$2.80 – $3.00ReaffirmedAug 4, 2026
Adjusted (3) R&D Expensesnon-GAAPFY2026$10.80B – $11.80B–LoweredNov 3, 2026
Adjusted (3) R&D Expensesnon-GAAPFY2026$10.50B – $11.50B$10.50B – $11.50BLoweredAug 4, 2026
Adjusted (3) SI&A Expensesnon-GAAPFY2026$12.50B – $13.50B–NewNov 3, 2026
Adjusted (3) SI&A Expensesnon-GAAPFY2026$12.50B – $13.50B$12.50B – $13.50BRaisedAug 4, 2026
Effective Tax Rate on Adjusted (3) Incomenon-GAAPFY202615%–NewNov 3, 2026
Effective Tax Rate on Adjusted (3) Incomenon-GAAPFY202615%15%ReaffirmedAug 4, 2026

Guidance vs results

The last range Pfizer gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Adjusted Diluted EPS$3.00 – $3.15$3.23Σ4QAbove range
FY2025Revenue$61.00B – $64.00B$62.70BΣ4QWithin range

Guidance history

Every forecast Pfizer put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 3, 2026Adjusted (3) diluted EPSFY2026$2.95 – $3.05New
Nov 3, 2026Effective Tax Rate on Adjusted (3) IncomeFY202615%New
Nov 3, 2026Adjusted (3) SI&A ExpensesFY2026$12.50B – $13.50BNew
Nov 3, 2026Adjusted (3) R&D ExpensesFY2026$10.80B – $11.80BLowered
Nov 3, 2026RevenuesFY2026$62.00B – $64.00BNew
Aug 4, 2026Adjusted (3) diluted EPSFY2026$2.80 – $3.00Reaffirmed
Aug 4, 2026Effective Tax Rate on Adjusted (3) IncomeFY202615%Reaffirmed
Aug 4, 2026Adjusted (3) SI&A ExpensesFY2026$12.50B – $13.50BRaised
Aug 4, 2026Adjusted (3) R&D ExpensesFY2026$10.50B – $11.50BLowered
Aug 4, 2026RevenueFY2026$60.50B – $62.50BRaised
May 5, 2026Adjusted (4) Diluted EPSFY2026$2.80 – $3.00Reaffirmed
May 5, 2026Effective Tax Rate on Adjusted (4) IncomeFY202615%Reaffirmed
May 5, 2026Adjusted (4) SI&A ExpensesFY2026$12.50B – $13.50BRaised
May 5, 2026Adjusted (4) R&D ExpensesFY2026$10.50B – $11.50BLowered
May 5, 2026RevenuesFY2026$59.50B – $62.50BReaffirmed
Feb 3, 2026Adjusted (3) Diluted EPSFY2026$2.80 – $3.00New
Feb 3, 2026Effective Tax Rate on Adjusted (3) IncomeFY202615%New
Feb 3, 2026Adjusted (3) SI&A ExpensesFY2026$12.50B – $13.50BNew
Feb 3, 2026Adjusted (3) R&D ExpensesFY2026$10.50B – $11.50BLowered
Feb 3, 2026RevenuesFY2026$59.50B – $62.50BNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Adjusted figures

Non-GAAP numbers Pfizer reports itself, taken from its earnings releases

MeasureQ3 FY2026Q2 FY2026Q1 FY2026FY2026Q4 FY2025FY2025
Full-Year 2026 Revenue Guidance–––$60.50B––
Adjusted (3) Income$4.99B$4.44B$4.29B–$3.79B$18.41B
Adjusted (3) Diluted EPS$0.87$0.77$0.75$2.80$0.66$3.22

Read from the company's own earnings releases; hover a figure for the sentence it came from. Companies choose what to leave out of an adjusted number and there is no standard for it, so these are not comparable between companies the way the audited statements are. Margins here are computed from the adjusted revenue of the same period.

Press releases

Releases Pfizer filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Update
  6. Results
  7. Results
  8. Results
  9. Results
  10. Update
  11. Results
  12. Results
  13. News
  14. News
  15. Results

See a number that looks wrong?